Bank of Montreal vs BIO-TECHNE Corp — how do they compare? Bank of Montreal trades at $180.98 (market cap $124.81B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: Bank of Montreal is far larger — about 11.2× BIO-TECHNE Corp's market cap, and Bank of Montreal pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| BMO | TECH | |
|---|---|---|
Market Cap | $124.81B | $11.12B |
Sector | Financials | Health |
52-Week High | $180.86 | $71.38 |
52-Week Low | $110.44 | $43.31 |
Dividend Yield | 2.77% | 0.45% |
Enterprise Value | — | $11.20B |
Trailing returns across standard periods
Latest headlines on both assets
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →